# Clinical Study of Efficacy and Safety of Raphamin in the Treatment of ARVI in Children 12-18 Years Old

> **NCT04918771** · PHASE3 · COMPLETED · sponsor: **Materia Medica Holding** · enrollment: 435 (actual)

## Conditions studied

- Acute Respiratory Viral Infection

## Interventions

- **DRUG:** Raphamin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04918771
- **Lead sponsor:** Materia Medica Holding
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-29
- **Primary completion:** 2023-07-21
- **Final completion:** 2023-07-21
- **Target enrollment:** 435 (ACTUAL)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04918771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04918771, "Clinical Study of Efficacy and Safety of Raphamin in the Treatment of ARVI in Children 12-18 Years Old". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04918771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*